Hereditary Cancer
Relevance: Medium-High
Most relevant for: People diagnosed with triple-negative breast cancer
Study: Study identifies genes associated with risk of triple-negative breast cancer
Panel testing can identify women who are at increased risk for breast cancer. However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown. A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)
READ MORE ›
Relevance: Medium
Most relevant for:
Article: Interview with Angelina Jolie's doctor promotes meatless diet and scientific inaccuracies
Dr. Kristi Funk, Angelina Jolie's Hollywood breast surgeon, is promoting her new book about breast cancer. This article from the UK newspaper The Times includes an interview with Funk about her book, which proposes that diet is responsible for breast cancer. This XRAYS addresses scientific inaccuracies in this article. (8/7/18)
READ MORE ›
Relevance: Medium
Most relevant for: People who are considering or have had direct-to-consumer testing
Study: Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations
A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)
READ MORE ›
Relevance: High
Most relevant for: Women at average risk for breast cancer
Study: Disparities in research impact breast screening guidelines
For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences. A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: Women with an MSH6 or PMS2 mutation
Study: Mutations in Lynch syndrome genes MSH6 and PMS2 may be associated with breast cancer
Some women with mutations in MSH6 and PMS2, two Lynch syndrome genes, may have a modest (2 to 3-fold) increased risk for breast cancer. (6/14/18 updated 09/25/19)
READ MORE ›
Relevance: High
Most relevant for: Women who have had or are considering mastectomy without reconstruction
Personal Story: Juliet's story: No reconstruction is a post-mastectomy option
In a March 2018 article from breastcancercare.org, Juliet conveys her personal experience with a breast cancer diagnosis and her decision to not have her breasts reconstructed after her mastectomy. She details the emotional complexity of her thought process and the empowerment she felt in her decisions. (5/24/18)
READ MORE ›
Relevance: High
Most relevant for: People with Icelandic heritage
Article: The right not to know when not knowing is dangerous
Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: Young high risk women
Study: Take your time, follow your heart: strategies for communication about family planning
When a woman is newly diagnosed with a BRCA mutation, she faces many risk management decisions. Although many of these decisions impact family planning, little guidance is available on how to communicate this information. This study examines female previvors’ advice on effective strategies for discussing family planning decisions. (03/28/18)
READ MORE ›
Relevance: Medium
Most relevant for: People who are considering or have had direct-to-consumer testing through 23andMe
Update: FDA approves at-home test kits for inherited cancer: how useful are they?
Genetic testing for health conditions (such as risk for cancer) typically requires a prescription from a doctor. Until recently, direct-to-consumer (DTC) genetic testing has focused on tests to learn your ancestry and find of unknown branches of family trees. A laboratory called 23andMe that provides direct-to-consumer genetic testing has been given FDA approval to report results for 3 mutations found in the BRCA1 and BRCA2 genes. The FDA statement provides details about this approval and warns people about the limitations of the 23andMe test. (03/19/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: People considering testing for an inherited gene mutation
Article: Insurance companies are more than curious about your genetic test results
An article on CBSNews.com addressed why insurance companies, particularly long-term insurance companies, might want to know which of their policy holders and potential policy holders have a gene that raises their risk for cancer. The article discusses genetic discrimination by insurance companies that provide long term care policies. Federal laws protect people with gene mutations from discrimination in health insurance. No such federal laws exist for life insurance, disability insurance or long term care. (3/13/18)
READ MORE ›